ICU Medical (NASDAQ:ICUI) Director Elisha Finney Sells 378 Shares of Stock

Posted by on Aug 12th, 2026

ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) Director Elisha Finney sold 378 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total value of $68,977.44. Following the sale, the director directly owned 4,871 shares of the company’s stock, valued at $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ICU Medical Trading Down 0.2%

NASDAQ:ICUI opened at $182.08 on Wednesday. The firm has a market cap of $4.55 billion, a P/E ratio of 154.31, a PEG ratio of 2.55 and a beta of 0.74. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The stock’s 50 day simple moving average is $153.69 and its 200-day simple moving average is $141.31. ICU Medical, Inc. has a 12-month low of $107.50 and a 12-month high of $192.85.

ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. During the same period last year, the company earned $2.10 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities analysts anticipate that ICU Medical, Inc. will post 6.51 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 price target on shares of ICU Medical in a research note on Friday. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. KeyCorp lifted their price objective on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Zacks Research cut ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, ICU Medical has an average rating of “Moderate Buy” and a consensus target price of $192.80.

Get Our Latest Report on ICU Medical

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP acquired a new stake in shares of ICU Medical during the 2nd quarter valued at approximately $26,000. Hilton Head Capital Partners LLC purchased a new position in ICU Medical in the 4th quarter valued at approximately $32,000. Covestor Ltd increased its stake in ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares in the last quarter. Strs Ohio raised its holdings in ICU Medical by 60.0% during the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the last quarter. Finally, Rockefeller Capital Management L.P. raised its holdings in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Read More

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.